We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+85.72%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$73.2M
Cap. Flow
-$340M
Cap. Flow %
-27.05%
Top 10 Hldgs %
36.58%
Holding
220
New
69
Increased
26
Reduced
46
Closed
56

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.6M
2
GOSS icon
Gossamer Bio
GOSS
+$8.85M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.61M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.3M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$6.53M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$23.1M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
3
IMVT icon
Immunovant
IMVT
+$12M
4
ARGX icon
argenx
ARGX
+$11.4M
5
VSTM icon
Verastem
VSTM
+$7.36M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
76
Xenon Pharmaceuticals
XENE
$6.2B
$3.74M 0.3%
298,173
-145,409
-33% -$1.85M
ASMB icon
77
Assembly Biosciences
ASMB
$516M
$3.67M 0.29%
13,122
– –
BHVN
78
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.66M 0.29%
50,000
-300,000
-86% -$16M
CLDX icon
79
CALL
Celldex Therapeutics
CLDX
$3.02B
$3.57M 0.28%
+274,500
New +$1.22M
ARVN icon
80
CALL
Arvinas
ARVN
$536M
$3.56M 0.28%
106,100
+50,000
+89% +$2.12M
NKTR icon
81
CALL
Nektar Therapeutics
NKTR
$2.41B
$3.47M 0.28%
+10,000
New +$3.12M
ZGNX
82
CALL
DELISTED
Zogenix, Inc.
ZGNX
$3.31M 0.26%
122,700
-90,200
-42% -$2.49M
VSTM icon
83
Verastem
VSTM
$536M
$3.29M 0.26%
159,444
-278,258
-64% -$7.36M
XLRN
84
PUT
DELISTED
Acceleron Pharma
XLRN
$3.29M 0.26%
34,500
-282,400
-89% -$27.2M
KYNB
85
PUT
Kyntra Bio
KYNB
$27.5M
$3.24M 0.26%
3,200
– –
ZYNE
86
CALL
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$3.24M 0.26%
+961,400
New +$4.55M
CLVS
87
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$3.22M 0.26%
476,900
-298,000
-38% -$2.26M
ACET icon
88
Adicet Bio
ACET
$84.7M
$3.12M 0.25%
+12,969
New +$2.55M
ICAD
89
DELISTED
iCAD Inc
ICAD
$3.12M 0.25%
312,268
+205,165
+192% +$2.22M
RIGL icon
90
Rigel Pharmaceuticals
RIGL
$704M
$3.08M 0.24%
168,053
– –
ALLK
91
DELISTED
Allakos
ALLK
$3.06M 0.24%
+42,536
New +$2.85M
AGTC
92
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.02M 0.24%
545,884
– –
ALBO
93
CALL
DELISTED
Albireo Pharma Inc
ALBO
$2.66M 0.21%
100,500
– –
SLNO
94
PUT
DELISTED
Soleno Therapeutics
SLNO
$2.62M 0.21%
+78,587
New +$3.41M
CASI
95
DELISTED
CASI Pharmaceuticals
CASI
$2.6M 0.21%
103,991
– –
APTX
96
DELISTED
Aptinyx Inc. Common Stock
APTX
$2.46M 0.2%
591,000
– –
KURA icon
97
CALL
Kura Oncology
KURA
$826M
$2.44M 0.19%
+150,000
New +$2.16M
ZYNE
98
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$2.33M 0.19%
+692,500
New +$3.27M
SLNO
99
CALL
DELISTED
Soleno Therapeutics
SLNO
$2.33M 0.19%
+70,000
New +$3.03M
NERV icon
100
CALL
Minerva Neurosciences
NERV
$187M
$2.32M 0.18%
80,200
+37,500
+88% +$2.2M
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Ikarian Capital held 220 positions worth $1.26B, down 5.5% from $1.33B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital withdrew a net $340M in Q2 2020, closing 56 positions and reducing 46 holdings. Its most notable exit was Acceleron Pharma, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 20% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Blueprint Medicines worth $15.7M.

  • Ikarian Capital's largest Q2 2020 buy was Blueprint Medicines: 201,662 shares worth $15.7M.
  • Ikarian Capital added most to bluebird bio in Q2 2020, an estimated $5.73M increase.
  • Ikarian Capital's biggest Q2 2020 reduction was BioXcel Therapeutics, cutting an estimated $17.3M.
  • Ikarian Capital fully exited Acceleron Pharma in Q2 2020, selling an estimated $23.1M.
  • Ikarian Capital's ten largest holdings make up 37% of its $1.26B portfolio in Q2 2020.
  • Ikarian Capital opened 69 new positions and closed 56 in Q2 2020.
  • Ikarian Capital's portfolio value fell 5.5% quarter-over-quarter to $1.26B.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.